At the news
? NEUTRALIMPACT 3/10 8-K filed Sep 1, 2026 at 09:23 ET
BioMarin completed its previously announced acquisition of Alesta Therapeutics B.V. on August 31, 2026, making Alesta a wholly owned subsidiary. The filing confirms deal closure but provides no financial terms, pipeline details, or strategic rationale, making it a routine administrative update with limited standalone trading impact.
- BioMarin completed the acquisition of Alesta Therapeutics B.V. on August 31, 2026.
- Alesta is now a wholly owned subsidiary of BioMarin.
- The acquisition was previously announced in an 8-K filed on August 18, 2026.
- No financial terms, deal value, or strategic details are disclosed in this filing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access